SEC Filings

AVEXIS, INC. filed this Form 8-K on 10/03/2017
Entire Document


Item 8.01.             Other Events.


On October 3, 2017, AveXis, Inc. (the “Registrant”) issued a press release to report top-line data from the Registrant’s Phase 1 clinical trial of AVXS-101 in spinal muscular atrophy Type 1. These data will be reported in a late-breaking breaking poster authored by Dr. Jerry Mendell, principal investigator in the trial and Curran-Peters Chair of Pediatric Research, Professor of Pediatrics and Neurology at the Research Institute at Nationwide Children’s Hospital and The Ohio State University, during the 22nd International Annual Congress of the World Muscle Society in Saint Malo, France. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.


Item 9.01.             Financial Statements and Exhibits.


(d) Exhibits




© AveXis, Inc. All Rights Reserved.